+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 40 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.

Age: 55Years - 90YearsAll GendersPhase 3
162 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ublituximab in older adults with relapsing forms of multiple sclerosis RMS, focusing on patients aged 55 to 80 years. This study addresses the gap in previous research where RMS patients over 55 were excluded, aiming to better understand how well this drug is tolerated in this population. It is a single-center, prospective cohort study sponsored by Neurology Center of New England P.C. Participants will receive ublituximab treatment, with the study lasting approximately 24 months and including about six visits to the study center. The study will monitor participants from baseline through month 24 or the end of the study, assessing the incidence of infections such as urinary tract infections and other active or chronic infections, as well as treatment-emergent and serious adverse events. During the study, participants will undergo various assessments including brain MRI scans to detect new or enlarging lesions, functional tests like the Expanded Disability Status Scale and Timed 25-Foot Walk Test, and blood tests measuring lymphocyte counts and immunoglobulin levels. Researchers will closely monitor safety and side effects throughout the 24-month period to gain insight into the drugs tolerance in older adults with RMS.

Age: 55Years - 80YearsAll Genders
1 location
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide alongside standard of care SoC compared to a placebo plus SoC in adult participants with major depressive disorder. This Phase 3 trial aims to delay the return of major depressive symptoms and is sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all administered by subcutaneous injection in addition to their standard treatment. The study includes a screening period lasting about one month, followed by a treatment period and potential post-treatment phase that together last at least 12 months. Throughout the trial, participants will self-inject the study medication and complete electronic and paper diaries along with questionnaires. Researchers will monitor the time to relapse of major depressive disorder and assess changes in depression rating scales, body weight, functional impairment, anxiety, quality of life, and other patient-reported outcomes. The follow-up period after treatment will last approximately 2 months.

Age: 18Years - 75YearsAll GendersPhase 3
180 locations
P

Actively Recruiting

Researchers are evaluating the drug brenipatide compared to a placebo to see if it works and is safe for adults with Alcohol Use Disorder AUD and hazardous alcohol use. This phase 3 study aims to understand how brenipatide affects drinking patterns over time. Participation in this trial will last about 56 weeks, with careful monitoring throughout. Participants will receive brenipatide or placebo through subcutaneous injections. The study includes escalating doses of brenipatide administered under the skin. Participants must self-inject the study drug or receive assistance from a trained support person if needed. The treatment phase is structured in parallel groups, comparing the drug against placebo. During the study, participants will attend regular visits and be asked to maintain study diaries and complete questionnaires. Researchers will assess changes in drinking patterns using the Timeline Followback Method, daily alcohol consumption, alcohol cravings, and health outcomes such as body weight and quality of life. Blood samples will be collected to measure brenipatide levels and monitor for any immune responses. The study includes safety monitoring and lasts for approximately 56 weeks.

Age: 18Years - 75YearsAll GendersPhase 3
115 locations
P

Actively Recruiting

Researchers are evaluating brenipatide, a drug given as a subcutaneous injection, compared to a placebo to understand its effects and safety in adults with moderate-to-severe Alcohol Use Disorder AUD. The study is a Phase 3, multicenter, randomized, double-blind trial sponsored by Eli Lilly and Company. The trial aims to assess changes in drinking patterns over a period of up to 56 weeks. Participants receive escalating doses of the study drug or placebo administered by subcutaneous injection. The study includes two experimental periods with LY3537031 and a placebo group. Participants will self-inject the study intervention, keep diaries, and complete questionnaires throughout the trial. The trial design includes random assignment to one of the study groups, and treatment is monitored over the full 56 weeks. During the study, participants will attend regular visits to monitor their alcohol consumption using the Timeline Followback method, assess alcohol cravings with the Penn Alcohol Craving Scale, and evaluate health outcomes including body weight and quality of life measures. Researchers will also study the drugs pharmacokinetics and the presence of anti-drug antibodies. Participation lasts about 56 weeks, with ongoing safety and efficacy assessments throughout this period.

Age: 18Years - 75YearsAll GendersPhase 3
117 locations
R

Actively Recruiting

Researchers are evaluating clazakizumab, a drug administered by subcutaneous injection, to study its effect on reducing high-sensitivity C-reactive protein hsCRP, a marker of inflammation, in adults with elevated hsCRP and increased risk for cardiovascular events. This phase 2b, randomized, double-blind, placebo-controlled study focuses on adults with established atherosclerotic cardiovascular disease or other risk factors such as obesity, type 2 diabetes, hypertension, or chronic kidney disease. The study aims to understand how clazakizumab compares to placebo in lowering inflammation related to cardiovascular risk. Participants will receive one of several doses of clazakizumab or a placebo via subcutaneous injection. The treatment period involves dosing and monitoring up to 32 weeks, with the primary outcome measured at 12 weeks and additional assessments at 24 weeks. The study includes a double-blind design where neither participants nor researchers know who receives the active drug or placebo. Pharmacokinetics of clazakizumab will also be evaluated during the trial. Throughout the approximately 9-month participation, participants will undergo blood tests to measure hsCRP levels at baseline and multiple follow-up points, including week 12 and week 24. Researchers will assess the percent change in hsCRP to evaluate inflammation changes. Safety and drug concentration will be monitored regularly. Participants will have scheduled visits for study drug administration and assessments, ensuring careful observation during the study period.

Age: 18Years +All GendersPhase 2
46 locations
E

Actively Recruiting

Researchers are evaluating whether donanemab, given as an intravenous infusion, can slow down the worsening of thinking, learning, memory, attention, and daily functioning in people with early cognitive decline and features of dementia with Lewy bodies. This phase 2 study focuses on participants aged 55 to 85 who show evidence of both amyloid and alpha-synuclein brain pathology. The trial is randomized and placebo-controlled to compare donanemab against a placebo. Participants will receive either donanemab or a placebo via IV infusion during the study. The treatment period lasts up to 52 weeks, during which various clinical and biomarker assessments will be conducted. The study includes monitoring for drug concentrations and immune responses. Both groups receive infusions under a quadruple-masked design to ensure unbiased results. Throughout the one and a half year participation, participants will be regularly evaluated using cognitive and functional tests like the Clinical Dementia Rating scale, Alzheimers Disease Rating Scales, and brain imaging to measure amyloid plaque levels. Safety assessments include monitoring for adverse effects and antibody development. Study partners familiar with the participants daily abilities provide additional information. The study aims to observe changes from baseline over the 52-week treatment period.

Age: 55Years - 85YearsAll GendersPhase 2
72 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of elismetrep, compared with placebo, for treating moderate to severe migraine in adults. This randomized, double-blind, multicenter outpatient study focuses on patients aged 18 to 75 who experience frequent migraine attacks. The trial aims to better understand elismetreps impact on migraine symptoms and relief. Participants are randomly assigned to receive a single oral dose of either elismetrep 10 mg, elismetrep 20 mg, or placebo. The study is conducted in a parallel design with triple masking to reduce bias. The primary focus is on pain freedom and relief from the most bothersome migraine symptoms within two hours after dosing. During the trial, participants will report their migraine symptoms and responses to treatment using study questionnaires and an electronic diary. Researchers will assess outcomes such as pain relief at 2 hours, sustained pain freedom up to 48 hours, freedom from nausea, photophobia, and phonophobia, and the need for rescue medication. Safety is monitored through adverse event reporting up to 8 days post-dose. The study is expected to last until December 2027.

Age: 18Years - 75YearsAll GendersPhase 3
72 locations
P

Actively Recruiting

Researchers are evaluating BHV-8000 in adults aged 40 to 80 diagnosed with early Parkinsons disease. The study aims to determine if BHV-8000 is effective, safe, and tolerable as a treatment. This Phase 23 trial is led by Biohaven Therapeutics Ltd. and includes a double-blind phase followed by an open-label phase to assess the treatments impact over time. Participants will be randomly assigned to receive either BHV-8000 at doses of 10 mg or 20 mg taken orally, or a matching placebo during the 48-week double-blind phase. After this, all participants enter a 48-week open-label phase where they receive BHV-8000. This design allows comparison between the study drug and placebo, followed by extended access to the active treatment. During the study, participants will be regularly assessed for Parkinsons disease progression using the Movement Disorder Society-Unified Parkinsons Disease Rating Scale MDS-UPDRS and other clinical measures. Safety will be monitored through recording adverse events and laboratory tests up to 96 weeks. The primary outcome is the time to first worsening event on the MDS-UPDRS Part II within 48 weeks. Participants are expected to remain in the study for up to 96 weeks of observation and treatment.

Age: 40Years - 80YearsAll GendersPhase 2Phase 3
25 locations
S

Actively Recruiting

Researchers are evaluating the safety and symptom improvement of ALKS 7290 tablets compared with placebo in adults diagnosed with Attention Deficit Hyperactivity Disorder ADHD. This phase 2, randomized, double-blind study aims to understand how ALKS 7290 affects ADHD symptoms over a four-week period. The study involves adult participants aged 18 to 65 who meet specific diagnostic criteria and have moderate or worse symptom severity. Participants will take ALKS 7290 tablets or placebo capsules daily by mouth for 4 weeks. The trial includes multiple dose levels of ALKS 7290 alongside a placebo group, with treatment effects compared across these groups. The study is designed with a parallel group model and triple blinding to ensure unbiased assessment. Throughout the study, participants will be regularly evaluated for changes in their ADHD symptoms using the Attention Deficit Disorder Investigator Symptom Rating Scale AISRS and the Clinical Global Impression-Severity scale. Safety is monitored by tracking adverse events up to six weeks. Participant health, medication stability, and symptom severity are assessed before and during the trial to measure treatment impact and ensure well-being.

Age: 18Years - 65YearsAll GendersPhase 2
28 locations

1-10 of 40

1